Objectif "Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to ""do better than Nature"", since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e) internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented." Champ scientifique natural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2013.2.3.0-1 - Innovation in vaccines Appel à propositions FP7-HEALTH-2013-INNOVATION-1 Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Contribution de l’UE € 1 218 786,00 Adresse DR MOLEWATERPLEIN 40 3015 GD Rotterdam Pays-Bas Voir sur la carte Région West-Nederland Zuid-Holland Groot-Rijnmond Type d’activité Higher or Secondary Education Establishments Contact administratif Wim Leep (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (7) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ARTEMIS BIO-SUPPORT B.V. Pays-Bas Contribution de l’UE € 918 211,00 Adresse MOLENGRAAFFSINGEL 10 2629 JD Delft Voir sur la carte Région West-Nederland Zuid-Holland Delft en Westland Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Eric Claassen (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Allemagne Contribution de l’UE € 526 360,00 Adresse GESCHWISTER SCHOLL PLATZ 1 80539 Muenchen Voir sur la carte Région Bayern Oberbayern München, Kreisfreie Stadt Type d’activité Higher or Secondary Education Establishments Contact administratif Gerd Sutter (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Aimm Therapeutics BV Pays-Bas Contribution de l’UE € 394 662,00 Adresse Meibergdreef 45 1105BA Amsterdam Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Willem Van Oort (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PROBIOGEN AG Allemagne Contribution de l’UE € 586 050,00 Adresse Goethestrasse 54 13086 Berlin Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Andrea Hauptmann Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée VIB VZW Belgique Contribution de l’UE € 520 260,00 Adresse SUZANNE TASSIERSTRAAT 1 9052 ZWIJNAARDE - GENT Voir sur la carte Région Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent Type d’activité Research Organisations Contact administratif Rik Audenaert Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée NOVAVAX AB Suède Contribution de l’UE € 296 550,00 Adresse KUNGSGATAN 109 753 18 Uppsala Voir sur la carte Région Östra Sverige Östra Mellansverige Uppsala län Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Erik Bergman (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Q-BIOLOGICALS NV Belgique Contribution de l’UE € 606 002,00 Adresse TECHNOLOGIEPARK 4 9052 Gent Voir sur la carte Région Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Annie Van Broekhoven (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
